Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. Genocea can screen pathogens in a high-throughput manner to rapidly identify antigens that result in the in vivo stimulation of protective CD8+ and CD4+ T-cells. These targets can be immediately incorporated into existing delivery systems to produce multivalent vaccine formulations that have the highest probability of generating protective immunity.